drugset / Trial / NCT06708624

Ocular Safety and Usability Study for FYB201 PFS

NCT06708624

Phase 4 Completed 31 enrolled Formycon AG
NaSingle-groupOpen-labelTreatment

Summary

The objective of the study is to assess the ocular safety of the FYB201 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.

Timeline

Start
2024-06-11
Primary completion
2024-08-08
Completion
2024-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal